Clinical trial
A Phase II Study of Eloxatin and Alimta in Combination With Bevacizumab in…
NCT00251524 · Veeda Oncology, Other · Completed
Key facts
| NCT number | NCT00251524 |
|---|---|
| Title | A Phase II Study of Eloxatin and Alimta in Combination With Bevacizumab in Advanced Non-Squamous NSCLC |
| Official title | A Phase II Study of Eloxatin and Alimta in Combination With Bevacizumab in Advanced Non-Squamous NSCLC |
| Lead sponsor | Veeda Oncology, Other |
| Collaborators | Sanofi Industry Eli Lilly and Company Genentech, Inc. |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Non-Small Cell Lung Cancer |
| Intervention type | Drug |
| Interventions | Bevacizumab, Oxaliplatin, Pemetrexed |
| Enrollment | 69 |
| Start date | Nov 1, 2005 |
| Primary completion | May 1, 2009 |
| Completion | May 1, 2009 |
| First posted | Nov 10, 2005 |
| Last update posted | May 11, 2012 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: